2022 September
archive,date,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive

September 2022

In patients with advanced NSCLC without EGFR, ALK, or ROS1 genomic tumor aberrations, treatment with cemiplimab plus chemotherapy showed a consistent relationship between ORR and baseline PD-L1 expression, with benefits versus chemotherapy alone seen across all levels of baseline PD-L1 expression; there was also a clear association between a continuous measure of changes in tumor size over time and baseline PD-L1 expression. Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in advanced NSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies. (Ref: Gogishvili M et al. Nat Med. Aug 25, 2022)
#oncologyresearch #clinicalresearch #clinicaldevelopment

In patients with pretreated germline BRCA1/2 breast cancer who had received a median of two prior chemotherapy lines for advanced disease, treatment with Lurbinectedin (a selective inhibitor of oncogenic transcription) showed an ORR of 28.6% (95% CI 11.3% to 52.2%), median DoR was 8.6 months, median PFS was 4.1 months and median OS was 16.1 months. No objective response was observed among patients who had received prior poly (ADP-ribose) polymerase inhibitors. This study showed the activity of lurbinectedin in germline BRCA1/2 breast cancer with a predictable and manageable safety profile. (Ref: Boni V et al, ESMO Open. Aug 26, 2022)
#oncologyresearch #clinicalresearch #clinicaldevelopment


Indoleamine 2,3- dioxygenase 1 (IDO1) is a cytosolic heme-containing enzyme that functions to catalyze tryptophan (Trp) degradation and kynurenine (Kyn) production, and the Trp:Kyn ratio reflects IDO1 activity. Tobacco carcinogens upregulate IDO1. Clinically, smoker patients with non-small-cell lung cancer (NSCLC) exhibited high IDO1 levels and low Trp/ Kyn ratios. In NSCLC patients, smokers with lower IDO1 responded better to anti-PD1 antibody treatment than those with higher IDO1. The data indicate that tobacco smoke induces IDO1 to catabolize Trp metabolism and immune suppression to promote carcinogenesis, and lower IDO1 might be a potential biomarker for anti-PD1 antibodies in smoker patients, whereas IDO1-high smoker patients might benefit from IDO1 inhibitors in combination with anti-PD1 antibodies. ( Ref: Liang F et al. Signal Transduct Target Ther. Sep 7, 2022)
#oncologyresearch #clinicalresearch #clinicaldevelopment